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OBJECTIVE—Two novel mutations (E1506D, E1506G) in the
nucleotide-binding domain 2 (NBD2) of the ATP-sensitive K
+
channel (KATP channel) sulfonylurea receptor 1 (SUR1) subunit
were detected heterozygously in patients with neonatal diabetes.
A mutation at the same residue (E1506K) was previously shown
to cause congenital hyperinsulinemia. We sought to understand
why mutations at the same residue can cause either neonatal
diabetes or hyperinsulinemia.
RESEARCH DESIGN AND METHODS—Neonatal diabetic
patients were sequenced for mutations in ABCC8 (SUR1) and
KCNJ11 (Kir6.2). Wild-type and mutant KATP channels were
expressed in Xenopus laevis oocytes and studied with electro-
physiological methods.
RESULTS—Oocytes expressing neonatal diabetes mutant chan-
nels had larger resting whole-cell KATP currents than wild-type,
consistent with the patients’ diabetes. Conversely, no E1506K
currents were recorded at rest or after metabolic inhibition, as
expected for a mutation causing hyperinsulinemia. KATP channels
are activated by Mg-nucleotides (via SUR1) and blocked by ATP
(via Kir6.2). All mutations decreased channel activation by
MgADP but had little effect on MgATP activation, as assessed
using an ATP-insensitive Kir6.2 subunit. Importantly, using wild-
type Kir6.2, a 30-s preconditioning exposure to physiological
MgATP concentrations (.300 mmol/L) caused a marked reduc-
tion in the ATP sensitivity of neonatal diabetic channels, a small
decrease in that of wild-type channels, and no change for E1506K
channels. This difference in MgATP inhibition may explain the
difference in resting whole-cell currents found for the neonatal
diabetes and hyperinsulinemia mutations.
CONCLUSIONS—Mutations in the same residue can cause
either hyperinsulinemia or neonatal diabetes. Differentially al-
tered nucleotide regulation by NBD2 of SUR1 can explain the
respective clinical phenotypes. Diabetes 60:1813–1822, 2011
T
he ATP-sensitive K
+ (KATP) channel plays a cen-
tral role in glucose-stimulated insulin secretion
from the pancreatic b-cell by linking the meta-
bolic state of the cell to its electrical excitability
(1–3). When plasma glucose levels rise, increased b-cell
metabolism closes KATP channels, producing a membrane
depolarization that opens voltage-dependent Ca
2+ chan-
nels, increases Ca
2+ inﬂux, and triggers insulin release (4).
Conversely, when plasma glucose levels fall, the decline in
metabolism opens KATP channels, suppressing electrical
activity and insulin secretion. As a consequence, mutations
in the b-cell KATP channel lead to disorders of insulin se-
cretion in humans and in animal models (5–11).
The b-cell KATP channel is a large macromolecular
complex in which four inwardly rectifying potassium
channel (Kir6.2) subunits form a central pore surrounded
by four regulatory sulfonylurea receptor (SUR1) subunits
(12,13). Both subunits are required for metabolic regula-
tion of channel activity, which is mediated by changes in
the intracellular concentrations of adenine nucleotides.
Binding of ATP or ADP to Kir6.2 in an Mg-independent
manner closes the channel, whereas interaction of Mg
nucleotides with SUR1 enhances channel opening (14–17).
The balance between these stimulatory and inhibitory
effects determines the level of channel activity.
Gain-of-function mutations in the Kir6.2 or SUR1 sub-
units of the KATP channel are a common cause of neonatal
diabetes, a rare inherited disorder characterized by the
development of diabetes within the ﬁrst 6 months of life
(5–7). The diabetes may be permanent or follow a
remitting–relapsing course (7). Fewer than 3% of patients
experience DEND (developmental delay with epilepsy,
muscle weakness and neonatal diabetes) syndrome; how-
ever, $20% manifest iDEND syndrome, an intermediate
condition consisting of developmental delay, muscle hy-
potonia, and neonatal diabetes (6). Almost all mutations,
whether in Kir6.2 or in SUR1, act by reducing the ability
of ATP to close the channel, thereby enhancing the KATP
current and preventing membrane depolarization when
b-cell metabolism increases (5,6,11,18–22). Sulfonylurea
drugs, which close KATP channels directly (23), stimulate
insulin secretion in most patients with neonatal diabetes
and have replaced insulin as the therapy of choice for this
condition (22,24,25).
Loss-of-function mutations in Kir6.2 or SUR1 give rise
to congenital hyperinsulinism, which is characterized by
continuous and unregulated insulin secretion despite very
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ORIGINAL ARTICLElow plasma glucose levels (8,9,26,27). Patients usually
present shortly after birth with persistent hypoglycemia
that requires immediate treatment to avoid brain damage.
Therapy in most cases involves a partial pancreatectomy,
but less severe forms of the disease can be managed with
the KATP channel-opener diazoxide.
Many disease-causing mutations in Kir6.2 and SUR1
have been described (3,7,18). However, to date, all muta-
tions that cause neonatal diabetes have been identiﬁed
in residues that differ from those that cause hyper-
insulinemia. We describe here the identiﬁcation and
functional characterization of mutations at the same res-
idue of SUR1 that can cause neonatal diabetes or its
converse, hyperinsulinism.
SUR1 belongs to the family of ATP-binding cassette
(ABC) transporters (28,29) and has 17 transmembrane he-
lices arranged in groups of 5 (N-terminal transmembrane
domain [TMD0]), 6 (TMD1), and 6 (TMD2). Two large
cytosolic loops follow TMD1 and TMD2 and contain the
nucleotide-binding domains (NBDs) that are characteristic
of ABC proteins. Each NBD consists of a Walker A motif,
a signature sequence, and a Walker B motif. The two NBDs
are sandwiched in head-to-tail manner to form two closely
linked nucleotide-binding sites (NBS) that comprise the
signature sequence of one NBD and the Walker A and B
motifs of the other (29).
The two NBS are not equivalent, however. Although
both hydrolyze MgATP, NBS1 appears to have a higher
afﬁnity for MgATP and a lower rate of hydrolysis (30). It is
also believed that the presence of MgADP at NBS2 is re-
quired to stimulate KATP channel activity (31). These dif-
ferences may arise because NBS2 has the consensus
sequence for ABC proteins, whereas that of NBS1 is de-
generate; in particular, the Walker B motif of NBD2 is
followed by a conserved catalytic glutamate residue (E1506),
whereas the equivalent residue in NBD1 is an aspartate.
This residue is critical in SUR1 function. In the closely
related ABC transporter MRP1, swapping the catalytic car-
boxylates of the two NBDs transfers many of the properties
of NBD1 to NBD2, and vice versa (32). Furthermore, the
mutation of E1506 to lysine (E1506K) results in reduced
channel activation by MgADP and is associated with hy-
perinsulinism (26,27). This article reports our investigation
of how the mutation of E1506 to aspartate (E1506D) or
glycine (E1506G) results in the opposite clinical condition
of neonatal diabetes.
RESEARCH DESIGN AND METHODS
Mutation detection. Genomic DNA was extracted from peripheral leukocytes
using standard procedures. The single-coding exon of KCNJ11 and the 39
exons of ABCC8 were ampliﬁed and sequenced as described (7). Reactions
were analyzed on an ABI 3730 Capillary sequencer (Applied Biosystems,
Warrington, U.K.). Sequences were compared with the reference sequences
NM_000525 and NM_000352.2, which incorporate the alternatively spliced
residue in exon 17 (L78208, L78224), using Mutation Surveyor 3.20 software
(SoftGenetics, State College, PA). Mutation testing was performed on parental
DNA extracted from peripheral leukocytes, and microsatellite analysis was
used to conﬁrm family relationships.
Molecular biology and oocyte preparation. Human Kir6.2 (Genbank
NM000525; E23 and I337) and rat SUR1 (Genbank L40624) were used. Site-
directed mutagenesis, synthesis of capped mRNA, and preparation of Xenopus
laevis oocytes were performed as reported (33). Oocytes were co-injected
with ;4 ng of wild-type or mutant SUR1 mRNA and ;0.8 ng Kir6.2 mRNA,
i n c u b a t e di nB a r t h ’s solution and studied 1–4 days after injection. To simulate the
heterozygous state, SUR1 was coexpressed with a 1:1 mixture of wild-type and
mutant Kir6.2. For each batch of oocytes, all homomeric or heterozygous muta-
tions were injected to enable direct comparison of their effects and to control for
batch-to-batch variation in expression levels (see Supplementary Data).
Electrophysiology. Whole-cell currents were recorded using a two-electrode
voltage clamp in response to voltage steps of 620 mV from a holding potential
of –10 mV, in a solution containing (in mmol/L) 90 KCl, 1 MgCl2, 1.8 CaCl2, and
5 HEPES (pH 7.4 with KOH) (33). Metabolic inhibition was induced by
3 mmol/L sodium azide, the KATP channel opener diazoxide (340 mmol/L) was
used to fully activate the channels, and tolbutamide (0.5 mmol/L) was used to
block KATP channels.
Macroscopic currents were recorded from giant inside-out patches at
260 mV; inward currents are shown as upward deﬂections of the current
trace. The pipette (external) solution contained (in mmol/L) 140 KCl, 1.2
MgCl2, 2.6 CaCl2, and 10 HEPES (pH 7.4 with KOH). The intracellular solution
contained (in mmol/L) 107 KCl, 11 EGTA, 2 MgCl2, 1 CaCl2, and 10 HEPES
(pH 7.2 with KOH), as well as nucleotides as indicated. The Mg-free in-
tracellular solution contained (in mmol/L) 107 KCl, 1 K2SO4, 10 EGTA, and 10
HEPES (pH 7.2 with KOH), as well as nucleotides as indicated.
ATP concentration-inhibition curves were constructed by alternating con-
trol and test solutions. To control for possible rundown, or activation by
MgATP, the conductance in the test solution was expressed as the mean of that
in control solution before and after nucleotide application. ATP concentration-
response curves were ﬁt with: G/Gc = 1/{1+[(ATP)/IC50]
h} (eq. 1), where (ATP)
is the ATP concentration, IC50 is the ATP concentration at which inhibition is
half maximal, and h is the slope factor.
In some experiments (Figs. 6 and 7), we used a conditioning prepulse of
variable [MgATP], followed by a test pulse of MgATP. Current during the test
pulse was expressed as a fraction of that in nucleotide-free solution.
Data are given as mean 6 SEM. Signiﬁcance was evaluated using the
Student t test.
RESULTS
Patient characteristics and genetics. We identiﬁed
novel heterozygous ABCC8 mutations, E1507D (c.4521G.
T) and E1507G (c.4520A.G), in two male probands. This
numbering refers to the L78208 human ABCC8 isoform that
encodes 1,582 amino acids and contains an additional resi-
due in NBD1; consequently, E1507 in our sequence is equiv-
alent to E1506 in that of Huopio et al. (26,27).
Proband 1 with the E1507D mutation weighed 2.9 kg at
birth (42 weeks’ gestation) and was diagnosed as insulin-
dependent at 10 weeks. At 30 weeks, the diabetes remitted
and insulin treatment was withdrawn. The patient is cur-
rently 4 years old, and the diabetes remains in remission.
Proband 2 weighed 3.5 kg at birth (40 weeks’ gestation)
and was diagnosed with diabetes at the age of 8 weeks.
After an E1507G mutation was identiﬁed, the patient was
successfully transferred from insulin to glibenclamide at
the age of 6 months. He was treated with glibenclamide
(2.5 mg, once daily) for ;4 months, at which time the di-
abetes remitted. The patient is currently 4 years old and
remains in remission. A family history of diabetes had not
been reported for either proband, and testing of parental
samples demonstrated that the E1507D and E1507G muta-
tions had each arisen de novo in the proband.
Effects on whole-cell KATP currents. We analyzed the
effects of mutations at E1506 of rat SUR1 (equivalent to
E1507 in the L78208 human ABCC8 isoform) on the met-
abolic regulation of the KATP channel by measuring whole-
cell currents. Wild-type (Kir6.2-SUR1) channels expressed
in Xenopus oocytes are normally closed, due to the high
intracellular ATP concentration ([ATP]i), but can be opened
by lowering [ATP]i using a metabolic inhibitor, such as so-
dium azide (Fig. 1). The subsequent addition of the KATP
channel-opener diazoxide (0.34 mmol/L) increased the cur-
rent only slightly, suggesting wild-type KATP channels are
almost fully activated by 3 mmol/L sodium azide. Tolbuta-
mide (0.5 mmol/L) almost completely blocked the current,
conﬁrming it ﬂows through KATP channels.
Mutations that reduce the channel ATP sensitivity nor-
mally increase the whole-cell current in the absence of
metabolic inhibition, reﬂecting the fact that they are less
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in resting current was observed for both homomeric
Kir6.2/SUR1-E1506D (homE1506D) and Kir6.2/SUR1-E1506G
(homE1506G) channels (Fig. 1). These currents were only
slightly enhanced by metabolic inhibition but were further
increased by diazoxide, suggesting azide-induced changes
in nucleotide concentrations may be insufﬁcient to fully
activate the mutant channels. As previously reported (27),
Kir6.2/SUR1-E1506K (homE1506K) currents were minimal
in both the absence and presence of azide but were slightly
increased by diazoxide. All mutant channels were strongly
blocked by tolbutamide.
The resting currents of heterozygous (het) E1506D and
hetE1506G channels were signiﬁcantly greater than wild-
type channels, which may explain why these mutations
cause neonatal diabetes. Azide strongly activated all het-
erozygous channels, and in the additional presence of
diazoxide there was a further increase. The maximal
hetE1506D current was not signiﬁcantly different from the
wild-type current, and that of het1506G channels was only
slightly smaller. These results suggest that hetE1506D and
hetE1506G channels retain metabolic sensitivity and that their
functional expression is similar to wild-type channels. The
maximal amplitude of hetE1506K channels was reduced, as
previously reported (27).
Tolbutamide (500 mmol/L) blocked hetE1506D currents
by 95 6 1% (n = 8), hetE1506G currents by 95 6 1% (n = 6),
and E1506K currents by 91 6 2% (n = 6) compared with
96 6 1% (n = 7) for wild-type channels.
Effects on KATP channel ATP sensitivity. In the cell-
attached conﬁguration, the homE1506D and homE1506G
currents were both larger than wild-type or homE1506K
currents, consistent with the whole-cell resting currents
(Supplementary Fig. 2A). However, no signiﬁcant difference
was found between wild-type and mutant hetE1506 channels.
There was no difference in the amplitude of wild-type
and homE1506K KATP currents recorded after patch ex-
cision (Table 1, Supplementary Fig. 2B), indicating the
smaller amplitude of homE1506K whole-cell currents is
not attributable to reduced channel expression. In con-
trast, homE1506D and homE1506G currents were both
substantially smaller. However, there was no difference
in hetE1506G currents and a ,50% decrease in het1506D
currents (Table 1, Supplementary Fig. 2B). This suggests
that the neonatal diabetes mutations have little (E1506D)
or no (E1506G) effect on expression levels of the KATP
channel in the heterozygous state. To determine the mo-
lecular mechanism of action of E1506 mutations, we studied
homomeric channels because the single population of chan-
nels simpliﬁes the analysis.
FIG. 1. Whole-cell KATP currents for wild-type and mutant channels. A–C: Representative whole-cell current amplitudes evoked by repeated voltage
steps from 210 to 230 mV for wild-type (A, WT), and homomeric (B, homE1506D) or heterozygous (C, hetE1506D) Kir6.2/SUR1-E1506D channels.
The bars indicate application of 3 mmol/L azide, 0.34 mmol/L diazoxide (Dz), and 0.5 mmol/L tolbutamide (Tb). The dashed line (- - -) indicates the
zero current level. Scale bars are 0.5 mA (y-axis) and 400 s (x-axis). D and E: Mean steady-state whole-cell KATP current amplitudes for wild-type
homomeric (D) and heterozygous (E) mutant channels. Currents were evoked by a voltage step from –10 to –30 mV before (control, ■) and after
(▨) application of 3 mmol/L azide, in the presence of 3 mmol/L azide plus 0.34 mmol/L Dz (□), and 3 azide + 0.5 mmol/L Tb (▧) for WT and SUR1
mutant channels, as indicated. The number of oocytes tested is given below the bars.* P £ 0.05, **P £ 0.01, ***P £ 0.001 against WT (Student t
test). The error bars show the SEM.
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homE1506D and homE1506G channels but no effect for
homE1506K channels (Fig. 2A–D); the concentration of
ATP producing half-maximal inhibition (IC50) was 21 mmol/L
for homE1506D, 19 mmol/L for homE1506G, 12 mmol/L for
homE1506K, and 13 mmol/L for wild-type (E1506) channels
(Table 1). The reduced ATP sensitivity of neonatal dia-
betes channels may account for the increased resting
whole-cell currents produced by these mutations.
We next analyzed the ATP sensitivity in the absence of
Mg
2+. This allows the effects of a mutation on ATP inhibition
at Kir6.2 to be isolated from its action on Mg-nucleotide
TABLE 1
ATP sensitivity of wild-type and mutant channels
Preincubation with zero ATP
Preincubation with 10 mmol/L
MgATP
Clone
Excised patch
current (nA) n
IC50 Mg
2+-free ATP
(mmol/L) n
IC50 MgATP
(mmol/L) n
% Current in
100 mmol/L
MgATP
IC50 MgATP
(mmol/L) n
% Current in
100 mmol/L
MgATP
SUR1 13.1 6 0.8 145 8.6 6 1.1 7 13.1 6 0.9 23 11 6 13 0 6 31 1 2 0 6 2
homE1506D 4.0 6 0.4* 96 8.8 6 1.0 7 20.6 6 1.5* 11 18 6 2† 78 6 3* 8 42 6 2*
homE1506G 1.9 6 0.2* 79 7.0 6 1.4 7 19.0 6 1.5† 10 16 6 1† 108 6 10* 7 51 6 4*
homE1506K 14.2 6 1.2 66 6.9 6 1.2 7 11.5 6 0.9 11 8 6 1 18.1 6 1.4† 78 6 1*
hetE1506D 7.5 6 1.7‡ 13 48 6 5† 92 8 6 2‡
hetE1506G 11.2 6 2.6 10 47 6 5† 72 6 6 3
hetE1506K 12.6 6 3.0 6 26 6 15 1 3 6 1‡
Data are mean 6 SEM; n = number of patches. Excised patch currents were measured immediately after excision into nucleotide-free solution
*P # 0.001, †P # 0.01, ‡P # 0.05, all against wild type (Student t test).
FIG. 2. ATP sensitivity of wild-type (WT) and mutant channels. A: Representative inside-out patch currents recorded in response to MgATP (100
mmol/L) for channels composed of WT Kir6.2 and WT or mutant SUR1, as indicated. The dashed lines (- - -) indicate the zero-current level. The solid
lines (–––) indicate nucleotide application. B: Mean relationship between KATP current (I), expressed relative to that in the absence of nucleotide
(Ic), and ATP concentration in the presence (B–D) or absence (E–G) of 2 mmol/L Mg
2+ for WT (○,---)a n dm u t a n t( ●, –––) channels. The lines are
drawn to eq. 1, with the following parameters (in mmol/L for IC50): B–D: wild-type (n = 23), IC50 = 12.2, h = 1.05; E–G: WT (n = 7), IC50 = 8.3, h =
1.09. B: Kir6.2/SUR1-E1506D (n = 11), IC50 = 20.1, h = 1.05. C: Kir6.2/SUR1-E1506G (n = 10), IC50 = 18.8, h = 0.93. D: Kir6.2/SUR1-E1506K (n = 11),
IC50 =1 1 . 0 ,h =1 . 1 4 .E:K i r 6 . 2 / S U R 1 - E 1 5 0 6 D( n =7 ) ,I C 50 =8 . 2 ,h =1 . 0 0 .F: Kir6.2/SUR1-E1506G (n =7 ) ,I C 50 = 6.9, h =0 . 8 6 .G:S U R 1 - E 1 5 0 6 K( n =7 ) ,
IC50 =6 . 4 ,h =1 . 0 0 .
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SUR1 in the absence of Mg
2+ (34). None of the homE1506
mutant channels showed changes in ATP sensitivity in
the absence of Mg
2+ (Fig. 2E–G, Table 1), suggesting that
the altered MgATP sensitivity of the homE1506D and
homE1506G channels is not a consequence of a reduced
ATP block at Kir6.2 but may arise from enhanced Mg-
nucleotide activation at SUR1.
The lack of an effect of the homE1506K mutation on
channel inhibition by ATP is in agreement with previous
studies (27).
Effects on MgADP activation of KATP channel. We next
examined Mg-nucleotide activation of wild-type and mutant
channels. As is well established, KATP currents decline in
amplitude after patch excision into nucleotide-free solution
(35). Application of 100 mmol/L MgADP reversed this run-
down and stimulated channel activity. Activation was quan-
tiﬁed by expressing the current in the presence of MgADP as
a fraction of that in the control solution before nucleotide
application.
Wild-type KATP currents were increased ;3.5-fold by 100
mmol/L MgADP (Fig. 3A and B). By contrast, MgADP
blocked all three mutant channels: by 77% for homE1506K,
55% for homE1506D, and 42% for homE1506G channels.
Qualitatively similar results were observed in the presence
of 100 mmol/L MgATP (Fig. 3C). The inability of MgADP to
FIG. 3. MgADP activation of wild-type (WT) and mutant channels. A: Representative inside-out patch currents recorded in response to application
of MgADP (100 mmol/L) for channels composed of WT Kir6.2 and WT or mutant SUR1, as indicated. The dashed lines (- - -) indicate the zero-current
level. The solid bars (■) indicate the application of nucleotide. Note that 100 mmol/L MgADP activates WT-SUR1 channels but blocks all the
mutant E1506 channels. B and C: MgADP activation of WT or mutant Kir6.2/SUR1-E1506 channels, as indicated. The number of patches is indicated
below the bars. B:K ATP current (I) in the presence of 100 mmol/L MgADP is expressed relative to the current in the absence of nucleotides (IC).
C:K ATP current (I) in the presence of 100 mmol/L MgADP and 100 mmol/L MgATP is expressed relative to the current in the presence of 100 mmol/L
MgATP alone (IATP). *P £ 0.05, **P £ 0.01, ***P £ 0.001 against wild type (Student t test). Statistical signiﬁcance between mutant E1506 channels
is reported in Supplementary Table 1. The error bars show the SEM.
FIG. 4. MgADP and MgATP activation of SUR1-E1506 mutations on a Kir6.2-G334D background. MgADP and MgATP activation of KATP channels
composed of Kir6.2-G334D and WT or mutant SUR1, as indicated. The number of patches is indicated below the bars. A: The maximal KATP current
after patch excision is expressed relative to that in the cell-attached patch. KATP current (I) in the presence of 100 mmol/L MgADP (B) or 100
mmol/L MgATP (C) is expressed relative to the current in the absence of nucleotides (IC). *P £ 0.05, **P £ 0.01, ***P £ 0.001 against wild type
(Student t test). Statistical signiﬁcance between mutant E1506 channels is reported in Supplementary Table 1. The error bars show the SEM.
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sence of ATP has been reported previously (27) and
probably underlies the failure of these channels to open
upon metabolic inhibition.
Previous studies have shown that in the absence of Mg
2+,
100 mmol/L ADP blocks wild-type KATP channels by ;60%
(16) by binding to the inhibitory site on Kir6.2. The fact
that homE1506D and homE1506G channels were blocked
,60% by 100 mmol/L MgADP suggests that MgADP may
retain some small stimulatory effect on these channels but
that this is masked by inhibition at Kir6.2. To assess if this is
correct, we examined the effect of MgADP on a Kir6.2-
G334D background. The G334D mutation abolishes block by
ATP (36) and thus allows the effects of Mg-nucleotides on
SUR1 to be studied in isolation from their effects at Kir6.2.
Effects of MgATP and MgADP activation on E1506
mutants expressed on the Kir6.2-G334D background.
Kir6.2-G334D/SUR1 (G334D/E1506) channels were highly
active in the on-cell conﬁguration (Fig. 4A) and the cur-
rents increased 1.4-fold on patch excision. No increase in
current was observed for the Kir6.2-G334D/SUR1-E1506D
(G334D/E1506D) or Kir6.2-G334D/SUR1-E1506G (G334D/
E1506G) channels; in contrast, the Kir6.2-G334D/SUR1-
E1506K (G334D/E1506K) currents increased 1.5-fold on
excision. This suggests that the G334D/E1506 and G334D/
E1506K channels were partially blocked under resting
conditions in the oocyte, whereas the G334D/E1506D and
G334D/E1506G channels were fully open. Larger ampli-
tudes were found for the G334D/E1506 (8.5 6 1.9 nA, n =
16) and G334D/E1506K (14 6 1.9 nA, n = 9) currents than
for the G334D/E1506D (1.0 6 0.2 nA, n = 11) or G334D/
E1506G (0.8 6 0.2 nA, n = 13) currents, again suggesting
that the E1506D and E1506G mutations may impair surface
expression in the homomeric state.
MgADP (100 mmol/L) activated G334D/E1506 channels
approximately ﬁvefold (Fig. 4B, Supplementary Fig. 1).
Its greater efﬁcacy compared with Kir6.2/SUR1 channels
(;3.5-fold, Fig. 3) presumably reﬂects a lack of MgADP
block at Kir6.2 when G334 is mutated. Activation of E1506
mutant channels was greatly reduced, but not completely
FIG. 5. Time course of MgADP and MgATP activation of KATP channels. Channels were composed of Kir6.2-G334D and wild-type (WT) or mutant SUR1
subunits, as indicated. Current activation and deactivation were ﬁt with a single exponential function. The number of patches is indicated below the
bars. Time constant of current activation (ton)b y1 0 0mmol/L MgADP (A)o r1 0 0mmol/L MgATP (B) is shown. Time constant of current deactivation
(toff)a f t e rr e m o v a lo f1 0 0mmol/L MgADP (C)o r1 0 0mmol/L MgATP (D)i ss h o w n .* P £ 0.05 **P £ 0.01, ***P £ 0.001 against wild-type, (Student
t test). Statistical signiﬁcance between mutant E1506 channels is reported in Supplementary Table 1. The error bars show the SEM. E:R e p r e s e n t a t i v e
current traces for WT and Kir6.2/SUR1-E1506D (E1506D) channels. The horizontal bar indicates the duration of application of 100 mmol/L MgATP.
The WT trace is interrupted to align the time point of ATP removal with that of the E1506D trace. Current amplitudes are normalized.
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increase in current in 100 mmol/L MgADP. Interestingly,
although MgATP (100 mmol/L) activated G334D/E1506
channels about as effectively as MgADP (100 mmol/L), it
was far more effective than MgADP at stimulating all three
double-mutant channels; MgATP increased the mutant
currents ;3-fold compared with 1.5-fold for MgADP (Fig.
4C, Supplementary Fig. 1). The difference in the extent of
activation of wild-type and neonatal diabetes channels was
not signiﬁcant.
The time course of channel activation by MgATP and
MgADP was also affected by mutations at E1506 of SUR1.
Activation of G334D/E1506 channels could be ﬁtted by one
exponential with a time constant (ton)o f;1 s for MgADP
and 2.5 s for MgATP (Fig. 5A and B). In contrast, the time
constant of activation by both MgADP and MgATP was
increased to ;20 s for all three SUR1 mutant channels.
The time constant of deactivation (toff) for the G334D/
E1506 channels was ;3 s for MgADP and ;5 s for MgATP
(Fig. 5C and D). The off-rate of MgADP was not signiﬁ-
cantly different for the G334D/E1506K channels but was
slower for the G334D/E1506D and G334D/E1506G channels,
with a toff of 10 and 11 s, respectively. The off-rate of MgATP
was signiﬁcantly less for all three mutant channels, with
a toff of 8.5 s for G334D/E1506K, 16 s for G334D/E1506G,
and 67 s for G334D/E1506D.
Effects on MgATP activation of the KATP channel.
These results suggest that MgATP is far more efﬁcient
than MgADP at activating the E1506 mutant channels. We
explored this possibility further using channels composed
of wild-type Kir6.2 and wild-type or mutant SUR1. We
measured the ATP concentration-inhibition curve after a
30-s exposure to 10 mmol/L MgATP (Fig. 6). Such ATP
preconditioning reduced the ATP sensitivity of the two
neonatal diabetic mutant channels but had little or no ef-
fect on wild-type or E1506K channels, respectively (Table 1).
As a consequence, the IC50 for the ATP block of the
homomeric and heterozygous E1506D and E1506G chan-
nels was signiﬁcantly greater than wild-type, whereas that
of hetE1506K was no different, and that of homE1506K
was actually slightly smaller (Fig. 6, Table 1). The effect of
MgATP preconditioning was dose-dependent (Fig. 7).
Preconditioning pulses of .300 mmol/L MgATP markedly
reduced the ability of 100 mmol/L MgATP to block E1506D
and E1506G channels but had only a small effect on wild-
type channels and no effect on the homE1506K channels.
Pre-exposure to 10 mmol/L MgADP, which fully blocked
the wild-type and mutant channels, did not affect the ability
of 100 mmol/L MgATP to block any of the four channel types
(data not shown).
DISCUSSION
Our results provide a functional explanation for why mu-
tation of E1506 in SUR1 to lysine (K) results in hyperin-
sulinism, whereas mutation of the same residue to
aspartate (D) or glycine (G) causes neonatal diabetes. This
occurs because the mutations have opposite effects on the
whole-cell KATP currents; hetE1506D and hetE1506G in-
crease resting whole-cell currents, whereas the hetE1506K
channels show no resting whole-cell currents and are
FIG. 6. ATP sensitivity of wild-type and mutant channels after preconditioning with 10 mmol/L MgATP. A: Representative homE1506D currents
recorded in response to different MgATP concentrations (as indicated), preceded by a preconditioning pulse in 10 mmol/L MgATP solution
(indicated by the unlabeled solid line [–––]) and followed by control (nucleotide-free) solution. The dashed lines (- - -) indicate the zero current.
B–D: Mean relationship between MgATP concentration and KATP current (I), expressed relative to that in the absence of nucleotide (Ic), after
30-s preincubation in 10 mmol/L MgATP for WT (○, n = 9), heterozygous (●), and homomeric mutant (▲) channels. Channels were composed
of Kir6.2 and wild-type or mutant SUR1 subunits, as indicated. B: homE1506D (n = 8), hetE1506D (n =9 ) .C:h o m E 1 5 0 6 G( n = 7), hetE1506G
(n = 7). D: homE1506K (n = 7), hetE1506K (n = 5). The lines are drawn to eq. 1, with the following parameters (in mmol/L for IC50): wild-type,
IC50 = 28, h = 1.2; homE1506D, IC50 = 78, h =1 . 2 ;h e t E 1 5 0 6 D ,I C 50 = 45, h = 1.2; homE1506G, IC50 = 105, h =1 . 3 ;h e t E 1 5 0 6 G ,I C 50 = 45, h = 1.3;
homE1506K, IC50 =1 8 ,h = 1.6; hetE1506K, IC50 =2 6 ,h = 1.4.
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crease in the resting b-cell KATP current would be expected
to produce b-cell hyperpolarization and reduce Ca
2+ in-
ﬂux and insulin secretion evoked by glucose, thereby
predisposing to diabetes. In contrast, a reduction in KATP
current will cause depolarization, maintained Ca
2+ inﬂux,
and persistent insulin secretion, giving rise to hyperin-
sulinism.
As reported for most other neonatal diabetes mutations
in SUR1 (18,21), the increase in the resting whole-cell
currents was relatively small. Such small changes are
consistent with the relatively mild, transient form of di-
abetes and the absence of neurological symptoms (6,18).
Resting currents in the pancreatic b-cell are likely larger
than those measured in the oocyte, perhaps because of
lower ATP levels. It is not evident why the diabetes remits,
but as is the case for other SUR1 mutations causing tran-
sient neonatal diabetes (29), it seems likely the diabetes
may later relapse and patients should be monitored for this
possibility.
Sulfonylureas are an effective therapy for most patients
with neonatal diabetes caused by KATP channel mutations
and are now the treatment of choice for this disease (24).
We observed that tolbutamide blocked hetE1506D and
hetE1506G currents as much as wild-type KATP channels,
which explains why our patients could be successfully
treated with glibenclamide.
Effects of mutations on whole-cell currents. So why
does the mutation of E1506 to K abolish resting whole-cell
KATP currents, whereas the mutation to E and G enhances
them? We favor the idea that this reﬂects differences in
the channel sensitivity to MgATP. We observed that the
neonatal diabetic mutant channels are substantially less
sensitive to ATP inhibition if they have been previously
exposed to physiological ATP concentrations of 1–10 mmol/L
(37). In contrast, this effect was very small for wild-type
channels and absent for E1506K channels. These results
are consistent with the differences in the resting whole-cell
current amplitude we measured in intact oocytes and
suggest that neonatal diabetic channels have larger resting
currents because they are less sensitive to ATP.
Metabolic inhibition will result in a fall in ATP and an
increase in MgADP, both of which will affect the response
of the KATP channel. Both reduced ATP inhibition at Kir6.2
and increased MgADP activation at SUR1 will contribute
to the increase in wild-type current and, to a lesser extent,
the heterozygous channels. The impaired response of the
homE1506K channels may be explained by their markedly
reduced MgADP activation, as previously suggested (27).
We suggest the small increase in the homE1506D and
homE1506G currents is because their reduced MgADP
activation is outweighed by their greatly reduced ATP
sensitivity, allowing the channels to open in response to
falling ATP levels.
Molecular mechanism. Because ATP sensitivity did not
change in the absence of Mg
2+, it appears that the muta-
tions do not reduce nucleotide block at Kir6.2. Rather, they
inﬂuence the interaction of Mg-nucleotides with SUR1.
E1506 lies within NBS2 of SUR1, close to the g-phosphate
of ATP and its associated Mg
2+ atom (38). The equivalent
residue in other ABC transporters is known to be involved
in nucleotide binding and ATPase hydrolysis (32) and its
mutation to aspartate dramatically reduces ATPase activ-
ity and the initial P (Pi) release in ABC proteins (39,40).
Thus mutation of E1506 in SUR1 is likely to alter the
conformation that Mg
2+ nucleotides adopt in the NBS and
thereby impair 1) nucleotide binding, and/or 2) ATPase
activity, and/or 3) the mechanism by which MgADP oc-
cupation at NBS2 is translated into channel opening.
It seems possible that the E1506 mutations trap NBS2 in
different conformational states of the ATPase cycle (Fig.
7C) that either promote channel activity (E, G) or do not
(K). All three mutations markedly reduce MgADP activa-
tion of the channel, arguing that occupancy of this state is
reduced and/or the translation of the MgADP-bound state
into channel activity is impaired. Mutation of the equivalent
residue in MRP1 to aspartate does not alter MgADP binding
(32), which suggests that SUR1-E1506D might bind MgADP
but that binding no longer leads to channel activation.
All mutations support MgATP activation of the channel,
as indicated by the use of a Kir6.2 ATP-insensitive mutation.
This suggests that MgATP binding/activation are relatively
FIG. 7. Concentration dependence of MgATP preconditioning on KATP
channel ATP sensitivity. A: Representative homE1506G currents re-
corded in response to test pulses of 100 mmol/L MgATP (unlabeled solid
line [–––]), preceded by a preconditioning pulse to a variable MgATP
concentration (10 mmol/L to 10 mmol/L, as indicated) and followed by
control (nucleotide-free) solution. B: MgATP concentration during the
conditioning prepulse plotted against the current during a 100 mmol/L
MgATP test pulse. Current is expressed as a fraction of that in control
(nucleotide-free) solution after the test pulse for wild-type (○, n =1 4 ) ,
homE1506D (●, n = 15), homE1506G (▲, n = 10), and homE1506K (■,
n = 8) channels. The lines are drawn through the points by eye. The
error bars show the SEM. C: The SUR1 ATPase catalytic cycle.
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channel is activated by occupancy of the MgATP-bound
state or the MgADP + Pi state, or both (Fig. 7C). Never-
theless, the ability of MgATP, but not MgADP, to stimulate
mutant channels almost as effectively as wild-type channels
argues that one or both of these states can do so. The
slower off-rate of MgATP seen with the neonatal diabetes
mutations (especially E1506D) may indicate that the chan-
nel becomes trapped in a particular state of the reaction
cycle that is associated with increased channel activity; for
example, the MgATP-bound or MgADP + Pi state. The off-
rate of MgADP was much faster than that of MgATP for the
E1506D channels, and MgADP had little stimulatory effect,
which supports arguments that it cannot be the MgADP-
bound state.
The most striking difference between the E1506K and
E1506G/E1506D channels is that shown in Figs. 6 and 7: pre-
exposure to millimolar concentrations of MgATP desensi-
tizes the channel to subsequent inhibition by a lower ATP
concentration. This cannot be due to an effect of MgATP on
kinases, for example, because this should be similar for all
channels. There are two obvious possibilities.
First, exposure to a saturating ATP concentration for an
extended period may force the channels into a state in
which NBS1 and NBS2 on all four subunits are both oc-
cupied by nucleotide, and this may lead to greater channel
activation. Second, it may relate to the slower off-rate of
MgATP of neonatal diabetes channels, which could main-
tain the channel in an activated state for an extended
period, so impairing ATP block. As shown previously, Mg-
nucleotide activation not only enhances channel activity
per se but also reduces ATP inhibition at Kir6.2 (41). In the
b-cell, where ATP levels are normally within the millimolar
range, this mechanism would result in reduced ATP in-
hibition and thus larger resting KATP currents.
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